GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “buy” rating reaffirmed by equities research analysts at Argus in a report released on Thursday. They presently have a $50.00 target price on the pharmaceutical company’s stock. Argus’ price objective indicates a potential upside of 24.38% from the stock’s previous close.

A number of other equities research analysts have also commented on the company. BidaskClub raised GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Citigroup Inc. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. Finally, Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. GlaxoSmithKline PLC currently has an average rating of “Hold” and a consensus target price of $46.00.

GlaxoSmithKline PLC (GSK) opened at 40.20 on Thursday. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.53. The stock has a market cap of $98.25 billion, a PE ratio of 39.96 and a beta of 1.03. The firm’s 50-day moving average price is $40.36 and its 200 day moving average price is $41.83.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities research analysts expect that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Argus Reiterates “Buy” Rating for GlaxoSmithKline PLC (GSK)” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/argus-reiterates-buy-rating-for-glaxosmithkline-plc-gsk/1537267.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC increased its position in GlaxoSmithKline PLC by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after buying an additional 1,389,238 shares in the last quarter. Fisher Asset Management LLC increased its position in GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after buying an additional 564,519 shares in the last quarter. Renaissance Technologies LLC increased its position in GlaxoSmithKline PLC by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after buying an additional 4,935,900 shares in the last quarter. Hotchkis & Wiley Capital Management LLC increased its position in GlaxoSmithKline PLC by 4.3% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock worth $338,377,000 after buying an additional 322,700 shares in the last quarter. Finally, Bank of America Corp DE increased its position in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after buying an additional 934,928 shares in the last quarter. Hedge funds and other institutional investors own 9.28% of the company’s stock.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.